Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1995-2-2
pubmed:abstractText
Comparison was made between the immunobiological and antigenic properties of two lipoteichoic acid (LTA) fractions (LTA-1 and -2) from Enterococcus hirae ATCC 9790, their glycolipid portions, and synthetic compounds partially mimicking the above bacterial products. The more lipophilic LTA-2 fraction was capable of inducing serum tumor necrosis factor alpha and interleukin-6 in muramyldipeptide-primed mice and serum gamma interferon in those primed with Propionibacterium acnes. The LTA-2 fraction also induced tumor necrosis factor alpha, interleukin-6, and thymocyte-activating factor (essentially interleukin-1) in murine peritoneal macrophage cultures. Consecutive intravenous injections of muramyldipeptide and the LTA-2 fraction in Meth A fibrosarcoma-bearing BALB/c mice caused hemorrhagic necrosis and marked regression leading to complete regression of the tumor with no accompanying weakening or lethal effects. The LTA-2 fraction was at least 10,000-fold less pyrogenic in rabbits than a reference endotoxic lipopolysaccharide. The more hydrophilic LTA-1 fraction, on the other hand, showed at most marginal activity in the in vivo and in vitro assays. Natural glycolipids (NGL-1 and -2) which were prepared from a chloroform-methanol extract of Streptococcus pyogenes and E. hirae cells, and comparable in structure to the lipid moieties of the LTA-1 and -2 fractions, respectively, were practically inactive in all of the assays. None of the test synthetic compounds was immunobiologically active, although synthetic partial counterparts of the structure of LTA proposed by W. Fischer (Handb. Lipid Res. 6:123-234, 1990) reacted with murine monoclonal antibody TS-2, which was raised against OK-432, a penicillin-killed S. pyogenes preparation, and capable of neutralizing the cytokine-inducing activities of the LTA-2 fraction.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-1103152, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-13641241, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-1414590, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-14206588, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-1500175, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-1510570, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-1718341, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-1901041, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-1937822, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-2099385, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-2410927, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-2676711, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-3260187, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-3279996, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-3361352, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-3435705, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-3491322, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-3888244, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-3896576, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-4303412, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-452765, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-4578758, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-46620, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-6190649, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-638158, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-669814, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-7462362, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-8225600, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-8294463, http://linkedlifedata.com/resource/pubmed/commentcorrection/7806384-8334107
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0019-9567
pubmed:author
pubmed:issnType
Print
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
57-65
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:7806384-Acetylmuramyl-Alanyl-Isoglutamine, pubmed-meshheading:7806384-Animals, pubmed-meshheading:7806384-Antigens, Bacterial, pubmed-meshheading:7806384-Antineoplastic Agents, pubmed-meshheading:7806384-Carbohydrate Sequence, pubmed-meshheading:7806384-Cytokines, pubmed-meshheading:7806384-Enterococcus, pubmed-meshheading:7806384-Fibrosarcoma, pubmed-meshheading:7806384-Glycolipids, pubmed-meshheading:7806384-Interferon-gamma, pubmed-meshheading:7806384-Interleukin-6, pubmed-meshheading:7806384-Lipopolysaccharides, pubmed-meshheading:7806384-Male, pubmed-meshheading:7806384-Mice, pubmed-meshheading:7806384-Mice, Inbred BALB C, pubmed-meshheading:7806384-Mice, Inbred C3H, pubmed-meshheading:7806384-Molecular Sequence Data, pubmed-meshheading:7806384-Propionibacterium acnes, pubmed-meshheading:7806384-Sarcoma, Experimental, pubmed-meshheading:7806384-Teichoic Acids, pubmed-meshheading:7806384-Tumor Necrosis Factor-alpha
pubmed:year
1995
pubmed:articleTitle
Molecular and structural requirements of a lipoteichoic acid from Enterococcus hirae ATCC 9790 for cytokine-inducing, antitumor, and antigenic activities.
pubmed:affiliation
Department of Microbiology and Immunology, Kagoshima University Dental School, Japan.
pubmed:publicationType
Journal Article, Comparative Study
More...